Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: An observational pilot study

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1480-1484

  Yildirim, Huseyin ^a   Metintas, Muzaffer ^a   Entok, Emre ^a   Ak, Guntulu ^a   Ak, Ilknur ^a   Dundar, Emine ^a   Erginel, Sinan ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Asbestos; Benign asbestos related pleural effusions; Diffuse pleural thickening; Malignant mesothelioma; Pleural disease

Indexed keywords

ASBESTOS; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASBESTOSIS; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MALIGNANT MESOTHELIOMA; NEEDLE BIOPSY; OBSERVATIONAL STUDY; PILOT STUDY; PLEURA BIOPSY; PLEURA DISEASE; PLEURA EFFUSION; PLEURAL FIBROSIS; PLEURISY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; THORACOSCOPY;

EID: 74249098576     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c0a7ff     Document Type: Article

References (19)

1. Metintas M, Metintas S, Hillerdal G, et al. Nonmalignant pleural lesions due to environmental exposure to asbestos: a field-based, cross-sectional study. Eur Respir J 2005;26:875-880.
2. Metintas M, Ak G, Erginel S, et al. A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience. Lung Cancer 2007;55:379-387.
3. Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 2006;21:146-153.
4. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 2004;45(Suppl 1):S73-S76.
5. Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med 2006;27:193-213.
6. Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr 1995;19:370-374.
7. Peacock C, Copley SJ, Hansell DM. Asbestos-related benign pleural disease. Clin Radiol 2000;55:422-432.
8. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-340.
9. Kramer H, Pieterman RM, Slebos DJ, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med 2004;45:995-998.
10. Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. AJR Am J Roentgenol 2004;182:983-989.
11. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-343.
12. Metintas M, Ucgun I, Elbek O, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol 2002;41:1-9.
13. Benamore RE, O'Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol 2005;60: 1237-1247.
14. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;114:713-722.
15. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 2000;17:377-383.
16. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005;129:1364-1370.
17. Armato SG III, Entwisle J, Truong MT, et al. Current state and future directions of pleural mesothelioma imaging. Lung Cancer 2008;59: 411-420.
18. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose. J Clin Oncol 2006;24:4587-4593.
19. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-768.